Given the increase in intestinal ER stress and oxidative stress as well as elevated expression of intestinal pro-inflammatory cytokines during obesity (after 22 weeks of HFD), we sought to determine whether administration of recombinant IL-22 could resolve mucosal barrier stress and inflammation. Here, IL22 is linked to obesity due to melanocortin 4 receptor deficiency.